Free Trial

Orchestra BioMed Q3 2023 Earnings Report

Orchestra BioMed logo
$4.92 +0.12 (+2.50%)
(As of 12/20/2024 05:16 PM ET)

Orchestra BioMed EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Orchestra BioMed Revenue Results

Actual Revenue
$0.42 million
Expected Revenue
$0.89 million
Beat/Miss
Missed by -$470.00 thousand
YoY Revenue Growth
N/A

Orchestra BioMed Announcement Details

Quarter
Q3 2023
Time
N/A
Wall Street Icon: “You must get on the right side of this thing” (Ad)

I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.

This market shakeup is going to be much more intense.

Orchestra BioMed Earnings Headlines

⭕ [URGENT] Buy Alert just triggered
My absolute favorite stock just hit a critical "buy now" trigger price.
See More Orchestra BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email.

About Orchestra BioMed

Orchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

View Orchestra BioMed Profile

More Earnings Resources from MarketBeat

Upcoming Earnings